Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
Sight Sciences, an eyecare technology company, announced its participation in the Piper Sandler 34th Annual Healthcare Conference in New York on November 30, 2022, at 11:30am ET. The company aims to transform patient care with innovative solutions for prevalent eye diseases. Interested individuals can access a live and archived webcast of the fireside chat via the company's website. Sight Sciences focuses on minimally invasive treatments, including the OMNI Surgical System for glaucoma and the TearCare System for dry eye disease.
- None.
- None.
MENLO PARK, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced plans to participate in the upcoming Piper Sandler 34th Annual Healthcare Conference in New York, NY.
Sight Sciences’ management is scheduled to participate in a fireside chat on Wednesday, November 30, 2022, at 11:30am ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: https://investors.sightsciences.com/.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The SION™ Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a trademark of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
What is the date and time of Sight Sciences' participation in the Piper Sandler Conference?
How can I watch Sight Sciences' fireside chat at the conference?
What innovative solutions does Sight Sciences focus on?
What is the primary purpose of the OMNI Surgical System?
What condition does the TearCare System address?
